Literature DB >> 20683369

Melanocytic nevi of the tarsal conjunctiva: clinicopathologic case series with review of literature.

Hyunjin Jane Kim1, Steven A McCormick, Sanjeev Nath, Bruce Moskowitz, Tatyana Milman.   

Abstract

PURPOSE: To describe 4 patients with histopathologically confirmed tarsal conjunctival nevi and to review the literature regarding nevi in this location.
METHODS: Clinicopathologic series of 4 cases diagnosed at the New York Eye and Ear Infirmary between January 1990 and April 2009. PubMed was searched for reported cases of tarsal conjunctival nevi.
RESULTS: Four patients (mean age 44 years, median 50 years, range 5-70 years) with tarsal conjunctival nevi were identified (3.4% of all histopathologically diagnosed conjunctival nevi). These lesions presented in adulthood (3 cases) and were associated with elevation/nodularity (3 cases), gray-brown coloration (3 cases), physician-documented growth (1 case), madarosis (1 case), and intrinsic vessels (1 case). Histopathology revealed combined nevi centered in the posterior lamella of the eyelid, predominantly in peri-Meibomian gland distribution. Review of the literature identified 10 previously reported cases of tarsal nevi with detailed clinicopathologic correlation in 3 of these patients.
CONCLUSIONS: Tarsal conjunctival nevi are rare. Adult presentation; subjective and objective evidence of growth; and associated inflammation, vascularity, and eyelid margin changes may make clinical distinction of tarsal nevi from melanoma challenging. Biopsy, therefore, is prudent as histopathology alone allows documentation of the benign nature of these lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683369     DOI: 10.1097/IOP.0b013e3181d18a64

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  1 in total

1.  Melanocytic Nevus of the Tarsal Conjunctiva.

Authors:  Bülent Yazıcı; Ayşe Dolar Bilge; Ayşe Yağcı; Faisal Naqadan; Filiz Altıntepe
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.